9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma

ConditionMalignant Tumor|Treatment Resistant Disorders|Tumor ProgressionEstimated Enrollment: 32Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: Eu-nr 2006-004076-13Study First Received: October 8, 2013Last Updated: October 8, 2013Estimated Primary Completion Date: October 2016Primary Outcome Measures:Maximal tolerable dose (phase I, ongoing)|ResponsesSponsors and Collaborators:Karolinska University Hospital|Cancerfonden|Cancer and Allergy Foundation|Cancerföreningen i Stockholm|Stockholm County Council, SwedenResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01959438...

Continue reading

An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

ConditionColorectal Cancer|Ovarian Cancer|Peritoneal DiseaseEstimated Enrollment: 150Age Group: 18 Years to 70 Years   (Adult, Senior)Gender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Cohort|Time Perspective: ProspectiveStudy ID Numbers: PN 1667Study First Received: March 29, 2016Last Updated: May 11, 2016Estimated Primary Completion Date: April 2021Primary Outcome Measures:Changes in invasive blood pressure in perioperative period|Changes in body temperature in perioperative period|Changes in cardiac output in perioperative period|Changes in arterial blood gas in perioperative period|Length of stay in intensive care unit|MortalitySponsors and Collaborators:Tata Memorial CentreResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02754115...

Continue reading

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

ConditionSolid TumorsEstimated Enrollment: 1706Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: EMR 100070-001|2013-002834-19Study First Received: January 14, 2013Last Updated: December 22, 2016Estimated Primary Completion Date: May 2018Primary Outcome Measures:Dose Limiting Toxicity|Confirmed Best Overall Response (BOR) as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) for Efficacy Expansion Cohorts|Number of subjects with Treatment-Emergent Adverse Events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.0|Pharmacokinetic parameters: AUC (0-t), AUC (0-infinity), λz, Cmax, Tmax, T(1/2) of avelumab|Immune-related Best...

Continue reading

A Study of BMS-986148 in Patients With Select Advanced Solid Tumors

ConditionAdvanced CancerEstimated Enrollment: 407Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: CA008-002|2014-002485-70Study First Received: January 14, 2015Last Updated: April 17, 2017Estimated Primary Completion Date: April 2019Primary Outcome Measures:Safety is measured by incidence of adverse events (AEs) at its worst grade, serious adverse events (SAEs) at its worst grade, adverse events leading to discontinuations, deaths, frequency of laboratory test toxicity grade shifting from baseline|Maximum observed serum or plasma concentration (Cmax) of BMS-986148|Time of maximum observed serum or plasma concentration (Tmax) of BMS-986148|Concentration at the...

Continue reading

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

ConditionSolid Tumors|Triple-Negative Breast Cancer|Non Small Cell Lung Cancer|Renal Cell Carcinoma|Mesothelioma|Fumarate Hydratase (FH)-Deficient Tumors|Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST)|Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors|Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations|Tumors Harboring Amplifications in the cMyc GeneEstimated Enrollment: 205Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: CX-839-001Study First Received: February 14, 2014Last Updated: August 18, 2016Estimated Primary Completion Date: June 2017Primary Outcome Measures:Safety and tolerability of CB-839: Incidence of adverse events|Pharmacokinetics: Area under the Curve (AUC) of CB-839 concentration in blood|Pharmacodynamics: %...

Continue reading

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

ConditionMalignant Neoplasm of Pancreas Metastatic to Peritoneal Surface|Malignant Peritoneal Mesothelioma|Peritoneal CarcinomatosisEstimated Enrollment: 168Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: 12-110|5P01CA132714-05Study First Received: May 28, 2014Last Updated: February 2, 2017Estimated Primary Completion Date: December 2017Primary Outcome Measures:Number of participants with adverse events|Time to disease progression|How long participants live after surgery|Changes in the immune systemSponsors and Collaborators:Pawel Kalinski|National Cancer Institute (NCI)|University of PittsburghResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02151448...

Continue reading

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

ConditionNon-Small Cell Lung Cancer|Small Cell Lung Cancer|Extrapulmonary Small Cell Cancer|Pulmonary Neuroendocrine Tumors|Thymic Epithelial TumorsEstimated Enrollment: 2000Age Group: 18 Years to 100 Years   (Adult, Senior)Gender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Cohort|Time Perspective: ProspectiveStudy ID Numbers: 140105|14-C-0105Study First Received: May 8, 2014Last Updated: April 21, 2017Estimated Primary Completion Date: April 30, 2024Primary Outcome Measures:Allow sample acquisition for use in the study of thoracic malignancies except mesothelioma.|Follow the natural history of patients with thoracic malignancies.|Conduct genomic, proteomic and immunological analyses on blood, tumor, body fluid and normal tissue in support of NIH translational trials to develop new therapeutic agents and...

Continue reading

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

ConditionCervical Cancer|Pancreatic Cancer|Ovarian Cancer|Mesothelioma|Lung CancerEstimated Enrollment: 136Age Group: 18 Years to 70 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Primary Purpose: TreatmentStudy ID Numbers: 120111|12-C-0111Study First Received: April 20, 2012Last Updated: April 20, 2017Estimated Primary Completion Date: December 31, 2018Primary Outcome Measures:Determine a safe dose of administration and determine if this approach will result in an objective tumor regression.|Determine the in vivo survival of CAR gene-engineered cells.Sponsors and Collaborators:National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01583686...

Continue reading

A Study of Atezolizumab in Advanced Solid Tumors

ConditionSolid TumorEstimated Enrollment: 725Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: MO29518|2015-000269-30Study First Received: May 28, 2015Last Updated: April 24, 2017Estimated Primary Completion Date: November 29, 2018Primary Outcome Measures:NPR: Percentage of Participants with CR, PR, or SD at 18 Weeks|NPR: Percentage of Participants with CR, PR, or SD at 24 weeks|Overall Response Rate (ORR): Percentage of Participants with CR or PR|Percentage of Participants by Best Overall Response (BOR)|Clinical Benefit Rate (CBR): Percentage of Participants with CR, PR, or SD Lasting for >/=6 Weeks|Duration...

Continue reading

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

ConditionMalignant Pleural Disease|Mesothelioma|Metastases|Lung Cancer|Breast CancerEstimated Enrollment: 24Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: 15-007Study First Received: April 2, 2015Last Updated: April 6, 2017Estimated Primary Completion Date: April 2018Primary Outcome Measures:Composite measure of severity and number of adverse events (AEs); changes in clinical laboratory test findings (hematologic and chemistry); and physical examination.|Changes in serum levels of the biomarker soluble mesothelin related peptide (SMRP)Sponsors and Collaborators:Memorial Sloan Kettering Cancer CenterResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02414269...

Continue reading